Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

Bioxyne lifts revenue 77% QoQ; Radiopharm listed on the Nasdaq in the December quarter; Tryptomine hits key milestones; Quarterly season is nearing its end, triggering a rush from ...

As per the recent earnings update by FactSet dated 24th January 2025, the Q4 2024 earnings season for the S&P 500 has seen a ...

A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...

We recently published a list of 10 Unstoppable Stocks to Buy in 2025. In this article, we are going to take a look at where ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...

"Beta Bionics joins IPO uptick, aims to raise $114.4m in Nasdaq listing" was originally created and published by Medical ...

Taysha Gene Therapies offers hope for Rett syndrome with innovative treatment, strong trial results, and promising regulatory ...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial ...

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and ...